Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
272lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Learning paths
Pick a track — progress rings update as you complete lessons.
7 lessons
8mResearchAdvanced
Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist
Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.
8mResearchAdvanced
Amycretin vs CagriSema: One Dual Agonist vs Two-Drug Amylin Stack
Same company family of ideas — GLP-1 + amylin — two product architectures. Here's how amycretin compares to CagriSema without fake head-to-head rankings.
8mProtocolsIntermediate
Cagrilintide Dosing Guide: Solo vs CagriSema 2.4 mg Weekly
Cagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.
9mPeptidesIntermediate
Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters
Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.
8mProtocolsIntermediate
Eloralintide + GLP-1 / Tirzepatide: The Amylin Add-On Stack Explained
Amylin + incretin is the stacking thesis behind CagriSema — and now eloralintide. Here's the clinical logic for combining pathways, without turning investigational drugs into DIY stacks.
8mResearchAdvanced
Eloralintide vs Cagrilintide: Amylin Agonists Compared
Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.
7mPeptidesIntermediate
CagriSema and Amylin: Why GLP-1 Stacks Are Changing in 2026
GLP-1 therapy is no longer just GLP-1. CagriSema, cagrilintide, petrelintide, and amycretin show why amylin is becoming a serious metabolic target.
Also available at /blog for legacy links.